APGE Stock Overview
Through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Apogee Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$38.00 |
52 Week High | US$72.29 |
52 Week Low | US$14.19 |
Beta | 0 |
11 Month Change | -20.88% |
3 Month Change | -42.19% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 78.99% |
Recent News & Updates
We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate
Jun 20Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play
Jun 18Recent updates
We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate
Jun 20Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play
Jun 18We're Interested To See How Apogee Therapeutics (NASDAQ:APGE) Uses Its Cash Hoard To Grow
Mar 05Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management
Mar 05We're Not Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn
Nov 21Shareholder Returns
APGE | US Biotechs | US Market | |
---|---|---|---|
7D | -2.5% | 2.1% | -0.5% |
1Y | n/a | 12.0% | 24.2% |
Return vs Industry: Insufficient data to determine how APGE performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how APGE performed against the US Market.
Price Volatility
APGE volatility | |
---|---|
APGE Average Weekly Movement | 8.5% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.5% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: APGE's share price has been volatile over the past 3 months.
Volatility Over Time: APGE's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2022 | 91 | Michael Henderson | www.apogeetherapeutics.com |
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD.
Apogee Therapeutics, Inc. Fundamentals Summary
APGE fundamental statistics | |
---|---|
Market cap | US$2.22b |
Earnings (TTM) | -US$103.55m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-21.5x
P/E RatioIs APGE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
APGE income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$103.55m |
Earnings | -US$103.55m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.77 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did APGE perform over the long term?
See historical performance and comparison